Week of October 13 - 19, 2019
Atgam® (Anti-thymocyte Globulin [Equine]) is used for a number of blood disorders, including aplastic anemia and Myelodysplastic Syndrome (MDS). It is also used to prevent the body from rejecting a kidney transplant, and in some cases, to prevent or treat Graft Versus Host Disease (GvHD).
Certain targeted therapies can lead to heart problems. Learn how to keep your heart healthy.
Certain cancer treatments can affect your eyes. Learn about how to keep your eyes healthy after treatment.
Anthracycline chemotherapies can cause heart problems. Learn how to keep your heart healthy.
In rare cases, some treatments for cancer can lead to a diagnosis of a second cancer at a later time. This is called secondary malignancy or secondary cancer.
Certain cancer treatments can lead to bladder problems. Learn how to keep your bladder healthy after cancer.
It is important to do what you can to keep your lungs healthy and learn about possible symptoms of lung issues to report to your healthcare providers.
An overview of respiratory gating, which involves certain breathing techniques used during radiation therapy. The most common types of respiratory gating are discussed.
Information about long term effects of cystectomy and urinary diversion.
An introduction to the regulation and safety of dietary supplements with focus on use during cancer treatment.
Information about health issues and concerns after thyroidectomy for thyroid cancer.
Fedratinib (Inrebic®) is a type of targeted therapy called a kinase inhibitor, used in the treatment of Myelofibrosis.
Is it ok if I lose weight during treatment?
Entrectinib (Rozlytrek™) is a kinase inhibitor used in the treatment of non small cell lung cancer and other solid tumors with certain neurotrophic receptor kinase (NTRK) genes.
FAQ about this common recommendation.
How do providers decide which people will benefit from chemotherapy with stage II colon cancer?
Darolutamide (Nubeqa®) is an androgen receptor inhibitor used in the treatment of patients with non-metastatic, castration-resistant prostate cancer.